ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

ASN / Education & Meetings / Kidney Week /

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: SA-PO717

Predictors of Bleeding Following Inpatient Percutaneous Kidney Biopsy

Session Information

Category: Glomerular Diseases

  • 1303 Glomerular Diseases: Clinical‚ Outcomes‚ and Trials

Authors

  • Katmeh, Tulayla, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
  • Thanamayooran, Aran, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
  • Bai, Isaac, Dalhousie University, Halifax, Nova Scotia, Canada
  • Berger, Geraint Christopher, Dalhousie University, Halifax, Nova Scotia, Canada
  • Day, Meghan, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
  • Huo, Bright, Dalhousie University, Halifax, Nova Scotia, Canada
  • Vinson, Amanda Jean, Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
  • Tennankore, Karthik K., Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
Background

Percutaneous diagnostic kidney biopsy is important in managing kidney disease, but less is known about predictors of bleeding following biopsy. The purpose of this study was to determine clinical risk factors for minor/major bleeding following percutaneous diagnostic kidney biopsy among admitted patients.

Methods

We analyzed a cohort of all adults that received an in-patient diagnostic kidney biopsy at a tertiary care center from 2014-2019. Biopsies for the diagnosis of kidney tumors were excluded. Outcomes of interest were minor bleeding (any of hemoglobin drop >10 g/L within 24 hours post biopsy, macrohematuria, hematoma on ultrasound) and major bleeding (need for blood transfusion or surgical intervention post biopsy). Predictors of major bleeding were analyzed using logistic regression; those factors significantly associated with bleeding using a P<0.05 were included in a multivariable model and reported using odds ratios (OR) with 95% confidence intervals (CI).

Results

Between 2014-2019, a total of 380 in-patient biopsies were performed. 221 (58.2%) of the patients were male, and mean age of the population was 57.3 ± 15.8 years. A minor bleed occurred in 131 (34.5%) of patients, and a major bleed occurred in 56 (14.7%) of patients. Risk factors for major bleeding are noted in Table 1. Factors significantly associated with major bleed included: creatinine 400-600 (OR. 7.46; 95%CI. 2.13-26.14); creatinine >600 or on dialysis (OR. 13.82; 95%CI. 4.04-47.25); structural heart disease (OR. 9.40; 95%CI. 1.33-66.47) and cerebrovascular disease (OR. 6.62; 95%CI. 1.47-29.78).

Conclusion

This study highlights risk factors associated with bleeding after inpatient percutaneous kidney biopsy which is of clinical importance for health care professionals. In future study we will derive and validate a risk prediction model for major and minor bleeding following biopsy.